Mascarenhas J - Search Results

1

Current therapeutic options in hairy cell leukemia.

Mikler E, Mascarenhas J. Mikler E, et al. Among authors: mascarenhas j. J Community Support Oncol. 2014 Mar;12(3):104-8. doi: 10.12788/jcso.0027. J Community Support Oncol. 2014. PMID: 24971416

2

Therapeutic options for patients with myelofibrosis in blast phase.

Mascarenhas J, Navada S, Malone A, Rodriguez A, Najfeld V, Hoffman R. Mascarenhas J, et al. Leuk Res. 2010 Sep;34(9):1246-9. doi: 10.1016/j.leukres.2010.05.008. Leuk Res. 2010. PMID: 20627294

3

Clarifying the use of ruxolitinib in patients with myelofibrosis.

Kremyanskaya M, Atallah EL, Hoffman R, Mascarenhas JO. Kremyanskaya M, et al. Oncology (Williston Park). 2013 Jul;27(7):706-14. Oncology (Williston Park). 2013. PMID: 23977767 Free article. Review.

4

Selective Janus associated kinase 1 inhibition as a therapeutic target in myelofibrosis.

Mascarenhas J. Mascarenhas J. Leuk Lymphoma. 2015;56(9):2493-7. doi: 10.3109/10428194.2015.1004670. Epub 2015 Feb 11. Leuk Lymphoma. 2015. PMID: 25586607 Review.

5

Discontinuing Tyrosine Kinase Inhibitor Therapy in Chronic Myelogenous Leukemia: Current Understanding and Future Directions.

Bhalla S, Tremblay D, Mascarenhas J. Bhalla S, et al. Among authors: mascarenhas j. Clin Lymphoma Myeloma Leuk. 2016 Sep;16(9):488-494. doi: 10.1016/j.clml.2016.06.012. Epub 2016 Jun 16. Clin Lymphoma Myeloma Leuk. 2016. PMID: 27406834 Review.

6

Current and evolving understanding of atypical chronic myeloid leukemia.

Schwartz LC, Mascarenhas J. Schwartz LC, et al. Among authors: mascarenhas j. Blood Rev. 2019 Jan;33:74-81. doi: 10.1016/j.blre.2018.07.004. Epub 2018 Jul 29. Blood Rev. 2019. PMID: 30078497 Review.

7

Myelofibrosis-Related Anemia: Current and Emerging Therapeutic Strategies.

Naymagon L, Mascarenhas J. Naymagon L, et al. Among authors: mascarenhas j. Hemasphere. 2017 Dec 20;1(1):e1. doi: 10.1097/HS9.0000000000000001. eCollection 2017 Dec. Hemasphere. 2017. PMID: 31723730 Free PMC article. Review.

8

The Myelodepletive Phenotype in Myelofibrosis: Clinical Relevance and Therapeutic Implication.

Marcellino BK, Verstovsek S, Mascarenhas J. Marcellino BK, et al. Among authors: mascarenhas j. Clin Lymphoma Myeloma Leuk. 2020 Jul;20(7):415-421. doi: 10.1016/j.clml.2020.01.008. Epub 2020 Feb 26. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32199764 Review.

9

Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.

Lancman G, Mascarenhas J, Bar-Natan M. Lancman G, et al. Among authors: mascarenhas j. J Hematol Oncol. 2020 Oct 2;13(1):131. doi: 10.1186/s13045-020-00968-1. J Hematol Oncol. 2020. PMID: 33008453 Free PMC article.

10

Novel therapeutics in myeloproliferative neoplasms.

Venugopal S, Mascarenhas J. Venugopal S, et al. Among authors: mascarenhas j. J Hematol Oncol. 2020 Dec 2;13(1):162. doi: 10.1186/s13045-020-00995-y. J Hematol Oncol. 2020. PMID: 33267911 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

576 results

Search Page

Filters